Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Coronary Syndrome | 34 | 2017 | 196 | 3.620 |
Why?
|
| Myocardial Infarction | 29 | 2018 | 485 | 2.660 |
Why?
|
| Emergency Service, Hospital | 38 | 2018 | 473 | 2.280 |
Why?
|
| Platelet Aggregation Inhibitors | 14 | 2015 | 83 | 1.870 |
Why?
|
| Chest Pain | 20 | 2018 | 207 | 1.750 |
Why?
|
| Anticoagulants | 13 | 2015 | 123 | 1.270 |
Why?
|
| Body Surface Potential Mapping | 4 | 2012 | 12 | 1.100 |
Why?
|
| Electrocardiography | 26 | 2016 | 632 | 1.080 |
Why?
|
| Risk Assessment | 23 | 2016 | 1435 | 0.960 |
Why?
|
| Emergency Medicine | 6 | 2010 | 120 | 0.880 |
Why?
|
| Myocardial Ischemia | 8 | 2012 | 106 | 0.850 |
Why?
|
| Critical Pathways | 5 | 2018 | 48 | 0.810 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 13 | 2013 | 30 | 0.760 |
Why?
|
| Hospitalists | 3 | 2008 | 9 | 0.700 |
Why?
|
| Emergency Treatment | 5 | 2010 | 41 | 0.670 |
Why?
|
| Registries | 15 | 2016 | 298 | 0.670 |
Why?
|
| Humans | 76 | 2018 | 32024 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 13 | 2011 | 407 | 0.570 |
Why?
|
| Angina, Unstable | 6 | 2007 | 21 | 0.550 |
Why?
|
| Middle Aged | 52 | 2018 | 11868 | 0.540 |
Why?
|
| Aged | 45 | 2018 | 10340 | 0.510 |
Why?
|
| Male | 57 | 2018 | 19195 | 0.510 |
Why?
|
| Decision Support Techniques | 4 | 2017 | 128 | 0.500 |
Why?
|
| Female | 55 | 2018 | 19953 | 0.470 |
Why?
|
| Myocardial Revascularization | 6 | 2016 | 41 | 0.470 |
Why?
|
| Health Services Accessibility | 3 | 2010 | 242 | 0.460 |
Why?
|
| Thrombosis | 3 | 2009 | 73 | 0.450 |
Why?
|
| Troponin | 10 | 2016 | 106 | 0.450 |
Why?
|
| Angina Pectoris | 3 | 2013 | 22 | 0.430 |
Why?
|
| Coronary Disease | 7 | 2007 | 213 | 0.420 |
Why?
|
| Professional Competence | 1 | 2012 | 19 | 0.420 |
Why?
|
| Peptide Fragments | 8 | 2015 | 398 | 0.410 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 33 | 0.410 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 58 | 0.400 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 160 | 0.400 |
Why?
|
| United States | 23 | 2016 | 3938 | 0.390 |
Why?
|
| Guideline Adherence | 8 | 2011 | 119 | 0.390 |
Why?
|
| Cardiology | 4 | 2016 | 99 | 0.380 |
Why?
|
| Coronary Thrombosis | 2 | 2008 | 14 | 0.380 |
Why?
|
| Algorithms | 4 | 2012 | 496 | 0.370 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 900 | 0.370 |
Why?
|
| Transportation of Patients | 1 | 2010 | 26 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 32 | 0.360 |
Why?
|
| Exercise Test | 5 | 2016 | 227 | 0.360 |
Why?
|
| Enoxaparin | 7 | 2015 | 20 | 0.360 |
Why?
|
| Coronary Artery Bypass | 8 | 2015 | 101 | 0.350 |
Why?
|
| Coronary Artery Disease | 3 | 2008 | 401 | 0.350 |
Why?
|
| Time Factors | 16 | 2016 | 2152 | 0.350 |
Why?
|
| Cardiology Service, Hospital | 3 | 2015 | 23 | 0.340 |
Why?
|
| Education, Medical, Continuing | 5 | 2014 | 55 | 0.340 |
Why?
|
| Hirudins | 8 | 2015 | 19 | 0.340 |
Why?
|
| Clinical Protocols | 4 | 2016 | 99 | 0.330 |
Why?
|
| Heparin | 7 | 2013 | 74 | 0.330 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 594 | 0.330 |
Why?
|
| Heart Diseases | 2 | 2011 | 116 | 0.320 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2009 | 61 | 0.310 |
Why?
|
| Creatine Kinase, MB Form | 7 | 2007 | 9 | 0.310 |
Why?
|
| Antithrombins | 3 | 2015 | 3 | 0.310 |
Why?
|
| Fibrinolytic Agents | 5 | 2009 | 70 | 0.310 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 35 | 0.300 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 69 | 0.300 |
Why?
|
| Adult | 21 | 2018 | 9366 | 0.300 |
Why?
|
| Aspirin | 6 | 2010 | 64 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2015 | 3317 | 0.290 |
Why?
|
| Predictive Value of Tests | 10 | 2017 | 878 | 0.280 |
Why?
|
| Hemorrhage | 6 | 2015 | 100 | 0.270 |
Why?
|
| Syncope | 1 | 2006 | 26 | 0.260 |
Why?
|
| Clinical Competence | 2 | 2009 | 333 | 0.250 |
Why?
|
| Patient Selection | 2 | 2011 | 277 | 0.240 |
Why?
|
| Credentialing | 1 | 2004 | 9 | 0.240 |
Why?
|
| Politics | 1 | 2004 | 22 | 0.240 |
Why?
|
| Patient Discharge | 4 | 2015 | 188 | 0.240 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 24 | 0.230 |
Why?
|
| North Carolina | 8 | 2016 | 1516 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Recombinant Proteins | 8 | 2015 | 247 | 0.230 |
Why?
|
| Ticlopidine | 5 | 2009 | 17 | 0.220 |
Why?
|
| Hospital Mortality | 7 | 2009 | 198 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Reproducibility of Results | 5 | 2016 | 765 | 0.220 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 300 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Survival Analysis | 6 | 2013 | 488 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 1324 | 0.210 |
Why?
|
| Delivery of Health Care | 3 | 2014 | 159 | 0.210 |
Why?
|
| Aged, 80 and over | 13 | 2016 | 4000 | 0.210 |
Why?
|
| Heart Conduction System | 3 | 2008 | 75 | 0.210 |
Why?
|
| Risk Factors | 12 | 2017 | 3869 | 0.200 |
Why?
|
| Peptides | 4 | 2013 | 119 | 0.200 |
Why?
|
| Troponin T | 4 | 2007 | 81 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2008 | 767 | 0.200 |
Why?
|
| Patient Care Team | 2 | 2014 | 130 | 0.190 |
Why?
|
| Cohort Studies | 6 | 2017 | 1831 | 0.190 |
Why?
|
| Logistic Models | 10 | 2010 | 781 | 0.180 |
Why?
|
| Evidence-Based Medicine | 5 | 2011 | 217 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2016 | 2283 | 0.180 |
Why?
|
| Patient Admission | 2 | 2011 | 60 | 0.180 |
Why?
|
| Acute Disease | 8 | 2011 | 254 | 0.170 |
Why?
|
| Creatine Kinase | 3 | 2003 | 11 | 0.170 |
Why?
|
| Coronary Angiography | 4 | 2018 | 152 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Isoenzymes | 3 | 2003 | 61 | 0.170 |
Why?
|
| Quality of Health Care | 3 | 2010 | 147 | 0.160 |
Why?
|
| Odds Ratio | 7 | 2011 | 474 | 0.150 |
Why?
|
| Early Diagnosis | 2 | 2008 | 62 | 0.150 |
Why?
|
| Diagnostic Errors | 2 | 2009 | 44 | 0.140 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 286 | 0.140 |
Why?
|
| Observation | 2 | 2013 | 25 | 0.140 |
Why?
|
| Triage | 3 | 2009 | 72 | 0.140 |
Why?
|
| Pyridines | 2 | 2013 | 76 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 94 | 0.130 |
Why?
|
| Death | 1 | 2015 | 50 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2016 | 117 | 0.130 |
Why?
|
| Prognosis | 7 | 2016 | 1505 | 0.130 |
Why?
|
| Cause of Death | 3 | 2016 | 238 | 0.130 |
Why?
|
| Hospitalization | 3 | 2010 | 470 | 0.130 |
Why?
|
| Documentation | 2 | 2004 | 46 | 0.120 |
Why?
|
| Age Factors | 5 | 2016 | 1194 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2016 | 3523 | 0.120 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 2280 | 0.120 |
Why?
|
| Decision Making | 1 | 2016 | 194 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 507 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2013 | 526 | 0.120 |
Why?
|
| Cyclic N-Oxides | 1 | 2013 | 8 | 0.110 |
Why?
|
| Heart Failure | 4 | 2007 | 636 | 0.110 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 61 | 0.110 |
Why?
|
| Troponin I | 3 | 2007 | 22 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 518 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 105 | 0.100 |
Why?
|
| Syndrome | 4 | 2007 | 73 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 565 | 0.100 |
Why?
|
| Health Personnel | 2 | 2011 | 121 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 72 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2012 | 202 | 0.100 |
Why?
|
| Singapore | 5 | 2016 | 10 | 0.100 |
Why?
|
| Cardiovascular Agents | 2 | 2009 | 23 | 0.100 |
Why?
|
| Hospital Costs | 1 | 2011 | 38 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2011 | 66 | 0.100 |
Why?
|
| Length of Stay | 4 | 2015 | 318 | 0.090 |
Why?
|
| Regional Health Planning | 1 | 2010 | 8 | 0.090 |
Why?
|
| Patient Care | 1 | 2011 | 31 | 0.090 |
Why?
|
| Inpatients | 1 | 2011 | 83 | 0.090 |
Why?
|
| Thrombolytic Therapy | 2 | 2008 | 63 | 0.090 |
Why?
|
| Critical Care | 1 | 2011 | 107 | 0.090 |
Why?
|
| Women | 1 | 2010 | 12 | 0.090 |
Why?
|
| Organizational Innovation | 1 | 2010 | 31 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 353 | 0.090 |
Why?
|
| Program Development | 1 | 2010 | 96 | 0.090 |
Why?
|
| Minority Groups | 1 | 2010 | 76 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2010 | 186 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2016 | 897 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2009 | 13 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 44 | 0.080 |
Why?
|
| Internet | 2 | 2007 | 195 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 42 | 0.080 |
Why?
|
| Emergency Medical Services | 2 | 2010 | 178 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2009 | 182 | 0.080 |
Why?
|
| Myocardial Reperfusion | 1 | 2007 | 10 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 1125 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 17 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2009 | 165 | 0.070 |
Why?
|
| Incidence | 3 | 2016 | 1200 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2008 | 90 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 105 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 265 | 0.070 |
Why?
|
| Sex Factors | 2 | 2005 | 663 | 0.070 |
Why?
|
| Insurance, Health | 2 | 2004 | 95 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2011 | 149 | 0.060 |
Why?
|
| Ventricular Function, Left | 1 | 2007 | 243 | 0.060 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2005 | 108 | 0.060 |
Why?
|
| Professional Autonomy | 1 | 2004 | 6 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 1 | 2004 | 13 | 0.060 |
Why?
|
| Specialty Boards | 1 | 2004 | 9 | 0.060 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2004 | 19 | 0.060 |
Why?
|
| Cost Savings | 2 | 2016 | 34 | 0.060 |
Why?
|
| Malpractice | 1 | 2004 | 21 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 2004 | 19 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2004 | 32 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2004 | 44 | 0.060 |
Why?
|
| Survival Rate | 2 | 2016 | 885 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 100 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2004 | 75 | 0.060 |
Why?
|
| Total Quality Management | 1 | 2002 | 18 | 0.050 |
Why?
|
| Aging | 1 | 2009 | 945 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 167 | 0.050 |
Why?
|
| Comorbidity | 3 | 2009 | 569 | 0.050 |
Why?
|
| American Medical Association | 2 | 2011 | 5 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 298 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2009 | 186 | 0.040 |
Why?
|
| Forecasting | 2 | 2010 | 144 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2008 | 15 | 0.040 |
Why?
|
| Tyrosine | 2 | 2008 | 23 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2016 | 37 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 244 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 141 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 27 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2006 | 195 | 0.030 |
Why?
|
| Research Design | 2 | 2007 | 312 | 0.030 |
Why?
|
| Age Distribution | 2 | 2006 | 207 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 2004 | 45 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 687 | 0.030 |
Why?
|
| Consensus | 2 | 2004 | 85 | 0.030 |
Why?
|
| Stents | 2 | 2008 | 178 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 355 | 0.030 |
Why?
|
| Health Resources | 1 | 2014 | 32 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 76 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 99 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 19 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 319 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2003 | 93 | 0.030 |
Why?
|
| Peer Review, Health Care | 1 | 2011 | 4 | 0.030 |
Why?
|
| Telecommunications | 1 | 2011 | 7 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 26 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2013 | 125 | 0.030 |
Why?
|
| Staff Development | 1 | 2011 | 16 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2011 | 4 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 20 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 47 | 0.020 |
Why?
|
| Adenosine | 1 | 2011 | 59 | 0.020 |
Why?
|
| Dobutamine | 1 | 2011 | 68 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 757 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 158 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 6 | 0.020 |
Why?
|
| State Health Plans | 1 | 2010 | 5 | 0.020 |
Why?
|
| Myocardium | 1 | 2011 | 186 | 0.020 |
Why?
|
| Heart | 1 | 2011 | 179 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 449 | 0.020 |
Why?
|
| Bradycardia | 1 | 2009 | 16 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 49 | 0.020 |
Why?
|
| Hypotension | 1 | 2009 | 47 | 0.020 |
Why?
|
| Benchmarking | 1 | 2009 | 23 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 162 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 273 | 0.020 |
Why?
|
| Thiophenes | 1 | 2008 | 23 | 0.020 |
Why?
|
| Atherectomy | 1 | 2008 | 4 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 54 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 30 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 59 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 131 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 115 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 11 | 0.020 |
Why?
|
| Systole | 1 | 2007 | 99 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1530 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 918 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 76 | 0.020 |
Why?
|
| Data Collection | 1 | 2006 | 180 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 81 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2007 | 170 | 0.020 |
Why?
|
| Physicians | 1 | 2006 | 158 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2007 | 349 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2003 | 94 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 67 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 195 | 0.010 |
Why?
|
| Continental Population Groups | 1 | 2004 | 237 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 981 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 544 | 0.010 |
Why?
|
| African Americans | 1 | 2003 | 1428 | 0.010 |
Why?
|